Chronic Spontaneous Urticaria
Chronic Spontaneous Urticaria
Advertisement
Cailin ConnerChronic Spontaneous Urticaria | July 10, 2024
Patients with chronic inducible urticaria respond well to antihistamines and omalizumab.
Read More
Cailin ConnerChronic Spontaneous Urticaria | July 9, 2024
A Danish cohort study found that individuals diagnosed with urticaria had a significantly increased risk of cancer.
Cailin ConnerChronic Spontaneous Urticaria | July 8, 2024
Higher neutrophil-lymphocyte ratio and systemic immune-inflammation index may indicate the transition from acute to CU.
Cailin ConnerChronic Spontaneous Urticaria | June 9, 2024
According to a recent study, omalizumab treatment in patients with CSU significantly alters cytokine levels.
Cailin ConnerChronic Spontaneous Urticaria | June 8, 2024
Approximately two-thirds of patients with CSU eligible for omalizumab prescriptions were not receiving them.
Cailin ConnerChronic Spontaneous Urticaria | June 7, 2024
Successful withdrawal of omalizumab was achieved in approximately 49.5% of patients with severe CSU.
Cailin ConnerChronic Spontaneous Urticaria | May 7, 2024
A study identified the potential of 2 biomarkers for monitoring disease activity and response in children with urticaria.
Cailin ConnerChronic Spontaneous Urticaria | May 7, 2024
Nearly one-third of patients with chronic spontaneous urticaria experience non-skin-related symptoms.
Cailin ConnerChronic Spontaneous Urticaria | April 23, 2024
C5a, IL-9, and apo A-IV were identified as potential biomarkers for predicting CSU severity.
Cailin ConnerChronic Spontaneous Urticaria | April 23, 2024
Autologous serum skin test positivity was associated with a delayed response to omalizumab treatment in patients with CSU.
Cailin ConnerChronic Spontaneous Urticaria | April 22, 2024
A study highlighted the underutilization of patient-reported outcome measures in the management of AD and CU.
Cailin ConnerChronic Spontaneous Urticaria | April 27, 2024
Disparities in access to omalizumab for patients with CSU significantly impact treatment patterns and health outcomes.
Cailin ConnerChronic Spontaneous Urticaria | April 22, 2024
CSU negatively affects quality of life, and patients with CSU are more likely to have worse sleep.
Cailin ConnerChronic Spontaneous Urticaria | March 15, 2024
Two phase 3 trials of dupilumab in chronic spontaneous urticaria demonstrated significant improvement in urticaria activity.
Cailin ConnerChronic Spontaneous Urticaria | March 15, 2024
According to a meta-analysis, there are statistically significant higher mean total IgE levels in responders to omalizumab th
Cailin ConnerChronic Spontaneous Urticaria | March 15, 2024
A twofold increase in dosage of desloratadine to 10 mg once daily significantly improves disease severity of CSU.
Cailin ConnerChronic Spontaneous Urticaria | March 15, 2024
The SDown-CSU study emphasized a global need for clear guidance on stepping down chronic spontaneous urticaria treatment.
Cailin ConnerChronic Spontaneous Urticaria | March 14, 2024
A prospective study found that omalizumab and dupilumab effectively managed moderate-to-severe allergic diseases.
Cailin ConnerChronic Spontaneous Urticaria | May 28, 2024
The cross-sectional study found that CSU exhibits similar prevalence in pediatric and adult patients.
Cailin ConnerChronic Spontaneous Urticaria | February 26, 2024
A global survey of allergists and immunologists revealed that 82% favored prescribing omalizumab for CSU.
Advertisement
Advertisement
Advertisement
Latest News

July 22, 2024